The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy
Cancer Cell International Open Access 24 November 2023
-
Current progress in innovative engineered antibodies
Protein & Cell Open Access 18 August 2017
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kingwell, K. CAR T therapies drive into new terrain. Nat Rev Drug Discov 16, 301–304 (2017). https://doi.org/10.1038/nrd.2017.84
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.84
This article is cited by
-
Extracellular targeted protein degradation: an emerging modality for drug discovery
Nature Reviews Drug Discovery (2024)
-
Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy
Cancer Cell International (2023)
-
Synapse-tuned CARs enhance immune cell anti-tumor activity
Nature Biotechnology (2023)
-
Human chimeric antigen receptor macrophages for cancer immunotherapy
Nature Biotechnology (2020)
-
Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy
Nature Biomedical Engineering (2018)
